KaloCyte Co-Founders Dr. Allan Doctor and Dr. Dipanjan Pan are among several experts featured in this article on blood substitute research, showcasing KaloCyte’s development of ErythroMer.

Chrysea and KaloCyte have entered into an exclusive license agreement, forging a global partnership that combines Chrysea’s synthetic biology expertise in production of biosynthetic hemoglobin with KaloCyte’s innovative artificial red blood cell technology.

KaloCyte’s Chief Scientific Officer, Dr. Allan Doctor, was interviewed on German television for this feature showcasing development of ErythroMer. (in German, subtitles unavailable).

Dr. Allan Doctor, co-founder and chief scientific officer at KaloCyte, speaks with host Jacob Goldstein explaining the complex science behind artificial blood, and how this innovation could help save millions of lives.

Scientists at the University of Maryland School of Medicine believe the technology could prove invaluable for paramedics, the military, and even future space missions where access to traditional blood transfusions is not possible.

NPR health correspondent Rob Stein expands on his recent visit with Dr. Allan Doctor at UMB, including photos featuring KaloCyte team members at work in the KaloCyte lab.

KaloCyte Co-founder Allan Doctor, MD, of the School of Medicine hosted a visit from NPR health correspondent Rob Stein, discussing the developmental progress of ErythroMer.

KaloCyte Co-founder Allan Doctor, MD, of the School of Medicine and Joga Gobburu, PhD, MBA, of the School of Pharmacy are optimistic they are on the cusp of developing the world’s first viable artificial blood.

KaloCyte’s three co-founders, Drs. Allan Doctor (CSO), Dipanjan Pan (CTO), and Phil Spinella (CMO) were among several experts interviewed for and quoted in this article on the history and current status blood substitute research, featuring KaloCyte’s development of ErythroMer.

KaloCyte, Inc., a pre-clinical biotech startup company developing a bio-inspired red blood cell substitute called ErythroMer™, announced today that it has been selected to join Blue Knight, a strategic collaboration between the Biomedical Advanced Research and Development Authority (‘BARDA’) and Johnson & Johnson’s global incubator network, JLABS, supporting early-stage innovation and incubation of science and technologies to improve health security and unlock new approaches to solving health issues.